To conclude, the GRASP‐LGMD consortium has identified a battery of COAs and PROs that are reliable and valid in evaluating functional abilities of patients with LGMDR1, in addition to quantifying functional differences based on age of symptom onset or variant classification. The gene discussed is CAPN3; the disease is limb-girdle muscular dystrophy.